{"id":"NCT00883740","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia","officialTitle":"Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2009-04-20","resultsPosted":"2011-08-10","lastUpdate":"2021-01-25"},"enrollment":119,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia","Sleep Disorders"],"interventions":[{"type":"DRUG","name":"Pregabalin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lyrica","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram)","primaryOutcome":{"measure":"Wake After Sleep Onset (WASO) at Weeks 5 and 11","timeFrame":"Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)","effectByArm":[{"arm":"Placebo","deltaMin":70.69,"sd":3.78},{"arm":"Pregabalin","deltaMin":51.54,"sd":3.78}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":50,"countries":["United States","Canada","Germany"]},"refs":{"pmids":["22232085"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":111},"commonTop":["dizziness","somnolence","headache","nausea"]}}